Pharmacogenomics of Antiplatelet Response (PARes-III)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02234427
Recruitment Status : Completed
First Posted : September 9, 2014
Results First Posted : January 9, 2017
Last Update Posted : January 9, 2017
Information provided by (Responsible Party):
Rehan Qayyum, Johns Hopkins University

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Basic Science
Condition: Atherosclerosis
Intervention: Drug: Aspirin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Aspirin Aspirin: 2-week aspirin therapy (81mg/day)

Participant Flow:   Overall Study
COMPLETED   33 [1] 
[1] One individual withdrew after first visit

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Aspirin Aspirin: 2-week aspirin therapy (81mg/day)

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 53.4  (10.3) 
[Units: Participants]
Count of Participants
Female      17  50.0% 
Male      17  50.0% 
Race/Ethnicity, Customized 
[Units: Participants]
African Americans   17 
Caucasians   17 

  Outcome Measures

1.  Primary:   Differential Gene Expression   [ Time Frame: 2-weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Rehan Qayyum
Organization: Johns Hopkins School of Medicine
phone: 410-955-7781

Responsible Party: Rehan Qayyum, Johns Hopkins University Identifier: NCT02234427     History of Changes
Other Study ID Numbers: PARes-III
First Submitted: September 5, 2014
First Posted: September 9, 2014
Results First Submitted: August 1, 2016
Results First Posted: January 9, 2017
Last Update Posted: January 9, 2017